Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Non Operating Income (2022 - 2025)

ARS Pharmaceuticals' Non Operating Income history spans 4 years, with the latest figure at $61000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 97.98% year-over-year to $61000.0; the TTM value through Dec 2025 reached $8.1 million, down 29.02%, while the annual FY2025 figure was $8.1 million, 29.02% down from the prior year.
  • Non Operating Income for Q4 2025 was $61000.0 at ARS Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.8 million in Q1 2023 and bottomed at -$151000.0 in Q1 2022.
  • The 4-year median for Non Operating Income is $2.8 million (2024), against an average of $2.1 million.
  • The largest annual shift saw Non Operating Income skyrocketed 6521.28% in 2023 before it crashed 97.98% in 2025.
  • A 4-year view of Non Operating Income shows it stood at $1.2 million in 2022, then soared by 164.99% to $3.1 million in 2023, then dropped by 1.08% to $3.0 million in 2024, then plummeted by 97.98% to $61000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Non Operating Income are $61000.0 (Q4 2025), $2.0 million (Q3 2025), and $2.7 million (Q2 2025).